title: First biosimilar drug set to enter US market.
authors.forename: Heidi
authors.initials: H
authors.lastname: Ledford
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics; D000068258:Bevacizumab; D059451:Biosimilar Pharmaceuticals / Q000737:chemistry / Q000191:economics* / Q000600:supply & distribution* / Q000627:therapeutic use; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D016568:Drugs, Generic / Q000191:economics; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000737:chemistry / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D006801:Humans; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D011994:Recombinant Proteins / Q000737:chemistry / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D035501:Uncertainty; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000068258:Bevacizumab; D000069585:Filgrastim